JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company’s abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 “was met with a lukewarm initial stock reaction that weakened over time,” the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis’ Scemblix.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics’ ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market
- Enliven Therapeutics Reports Q1 Results and Pipeline Progress
- Enliven price target raised to $40 from $39 at H.C. Wainwright
- Enliven Therapeutics: Strategic Focus and Promising Developments Justify Buy Rating
- Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML